GSK has counted the cost of narrower US recommendations on the use of RSV vaccines, which caused a 51% decline in sales of its Arexvy shot in 2024, but still managed to post reasonable sales ...
Hosted on MSN2mon
FDA Adds Guillain-Barre Syndrome Warning to Two RSV VaccinesThe FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).
Hosted on MSN1mon
European Equities Rise in Friday Trading; Germany GDP Edges Up in Q3In Germany, gross domestic product grew 0.1% in ... Labor and Welfare has approved an extension of the indication of Arexvy to prevent respiratory syncytial virus disease to include adults aged ...
Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine, which was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated $1.6 billion in sales in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback